FDA grants Priority Review For Promacta/Revolade (Eltrombopag)
- Details
- Category: GlaxoSmithKline
GlaxoSmithKline announced that the United States Food and Drug Administration (FDA) has granted Priority Review for Promacta®/Revolade® (eltrombopag) for the short-term treatment of patients with chronic idiopathic thrombocytopenic purpura (ITP).
Court decides against Bayer's Yasmin® patent
- Details
- Category: Bayer
US District Court for the District of New Jersey ruled against the validity of Bayer Schering Pharma's 531 patent for the companyâs oral contraceptive Yasmin, the result of a patent challenge by generic manufacturer Barr Laboratories. Bayer disagrees with the court's decision and will consider its legal options in this regard. The company will continue to vigorously defend its
intellectual property.
Pfizer to Acquire Serenex to Extend Oncology Pipeline
- Details
- Category: Pfizer
Pfizer Inc today announced that it has entered into an agreement to acquire Serenex, Inc., a privately-held biotechnology company with a Phase I clinical candidate and an extensive compound library that targets Heat Shock Protein 90 (Hsp90), an exciting target in the fight against cancer.
Update on GSK's malaria treatments: Dacart and Lapdap
- Details
- Category: GlaxoSmithKline
Malaria is a devastating disease killing over one million people, mostly young children and pregnant women every year. There is an urgent need for new medicines to treat the disease as resistance builds to older treatments. GSK and Medicines for Malaria Venture (MMV) are working in partnerships on a number of projects dedicated to finding new malaria treatments.
Johnson & Johnson Diabetes Institute To Provide Education, Training to Health Professionals
- Details
- Category: Business
With mounting evidence that many health professionals lack the training and skills to combat the nation's growing epidemic of diabetes, the Johnson & Johnson Diabetes Institute, LLC opened its first training center in the U.S. to improve how practitioners deliver diabetes care in local communities.
Forest Laboratories, Inc. Announces Amendment to Bystolic(TM) (nebivolol) Agreement
- Details
- Category: Product
Forest Laboratories Holdings, Ltd., a wholly owned subsidiary of Forest Laboratories, Inc. (NYSE: FRX), announced that it and Mylan Inc. (NYSE: MYL) have amended their January 2006 agreement to commercialize, develop and distribute the novel beta blocker Bystolic(TM) (nebivolol), which is currently approved in the United States for the treatment of hypertension.
The Bayer Group once again considerably improved its sales and earnings in 2007
- Details
- Category: Bayer
The Bayer Group once again considerably improved its sales and earnings in 2007, and also exceeded its performance targets. "2007 was Bayer's most successful year to date," said Management Board Chairman Werner Wenning on Thursday at the Spring Financial News Conference in Leverkusen.
More Pharma News ...
- Celebrity Chef Offers Recipes and Shortcuts in the Kitchen to People with Rheumatoid Arthritis
- AstraZeneca Provides Update On RECENTIN⢠Clinical Development Programme
- Pfizer Voluntarily Withdraws Lipitor Advertising Featuring Dr. Robert Jarvik
- Novartis Vaccines Institute for Global Health (NVGH) is the first institute with nonprofit mission
- Nycomed creates a leading specialty pharmaceutical player in dermatology
- AstraZeneca To Appeal Judgment In Alabama Medical Pricing Case
- Shire plc accelerating new product sales drive revenue growth of 36%